1 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
Follow Biliary Tract Cancers: new trials by email Literature Review of Biliary Tract Cancers trials Research Report on Biliary Tract Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer Daraxonrasib - Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 55 | 2026-11-01 | 2026-11-10 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Pembrolizumab, Lenvatinib - Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 2 | Completed | Merck Sharp & Dohme LLC | 611 | 2019-02-12 | 2026-05-04 |
Biliary Tract Neoplasms (3) · Carcinoma (1) · Cholangiocarcinoma (1) · Cirrhosis, Familial, with Pulmonary Hypertension (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioblastoma (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Biliary Tract Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Gastrointestinal Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Adnexal Diseases (1) · Astrocytoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Colonic Diseases (1) · Endocrine Gland Neoplasms (1)
DEAE-Dextran (1) · anlotinib (1) · lenvatinib (1) · pembrolizumab (1)
Merck Sharp & Dohme LLC (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · West China Hospital (1)
United States (2) · Argentina (1) · Australia (1) · Canada (1) · Chile (1) · China (1) · Colombia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Russia (1) · South Korea (1) · Spain (1) · Switzerland (1)
Nilo Azad, MD (1)
PMID 38718741, PMID 39031824, PMID 40808295, PMID 41747221, PMID 41763955
2018 (1)